Utilization of nanoparticle technology in rheumatoid arthritis treatment

Biomedicine and Pharmacotherapy

Volumn 80, Issue , 2016, Pages 30-41

  Dolati, Sanam ^a,b   Sadreddini, Sanam ^c,d   Rostamzadeh, Davoud ^a,b   Ahmadi, Majid ^a,b   Jadidi Niaragh, Farhad ^e   Yousefi, Mehdi ^c,d  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Drug delivery; Nanoparticles; Rheumatoid arthritis; Treatment

Indexed keywords

ALBUMIN; ANTIBODY; BIOLOGICAL PRODUCT; CHITOSAN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DRUG CARRIER; GLUCOCORTICOID; GOLD NANOPARTICLE; IRON OXIDE; LIPOSOME; NANOCARRIER; NANOPARTICLE; NONSTEROID ANTIINFLAMMATORY AGENT; POLYMER;

COLLAGEN-INDUCED ARTHRITIS; ENVIRONMENTAL FACTOR; GENE THERAPY; HEREDITY; HUMAN; NANOTECHNOLOGY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SEROLOGY; SYNOVIOCYTE; ARTHRITIS, RHEUMATOID; CHEMISTRY; PROCEDURES;

ARTHRITIS, RHEUMATOID; DRUG CARRIERS; HUMANS; NANOPARTICLES; NANOTECHNOLOGY;

EID: 84960444567     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2016.03.004     Document Type: Review

References (114)

1. Mitragotri S., Yoo J.-W. Designing micro-and nano-particles for treating rheumatoid arthritis. Arch. Pharmacal Res. 2011, 34:1887-1897.
2. Schurgers E., Billiau A., Matthys P. Collagen-induced arthritis as an animal model for rheumatoid arthritis: focus on interferon. J. Interferon Cytokine Res. 2011, 31:917-926.
3. Kourilovitch M., Galarza-Maldonado C., Ortiz-Prado E. Diagnosis and classification of rheumatoid arthritis. J. Autoimmun. 2014, 48:26-30.
4. Yousefi B., Jadidi-Niaragh F., Azizi G., Hajighasemi F., Mirshafiey A. The role of leukotrienes in immunopathogenesis of rheumatoid arthritis. Mod. Rheumatol. 2014, 24:225-235.
5. Viatte S., Plant D., Raychaudhuri S. Genetics and epigenetics of rheumatoid arthritis. Nat. Rev. Rheumatol. 2013, 9:141-153.
6. Ospelt C., Gay S. Epigenetic Epidemiology of Inflammation and Rheumatoid Arthritis 2012, 289-305. Epigenetic Epidemiology: Springer.
7. Pham C.T. Nanotherapeutic approaches for the treatment of rheumatoid arthritis. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2011, 3:607-619.
8. da Costa Moura C. Development of Multifunctional Nanoparticles for Targeted Therapy and Imaging of Rheumatoid Arthritis: Faculty of Engineering 2013, University of Porto.
9. Paulissen S.M., van Hamburg J.P., Dankers W., Lubberts E. The role and modulation of CCR6+ Th17 cell populations in rheumatoid arthritis. Cytokine 2015, 74:43-53.
10. Roy K., Kanwar R.K., Kanwar J.R. Molecular targets in arthritis and recent trends in nanotherapy. Int. J. Nanomed. 2015, 10:5407.
11. Danks L., Takayanagi H. Immunology and bone. J. Biochem. 2013, 154:29-39.
12. Szekanecz Z., Koch A.E. Angiogenesis and its targeting in rheumatoid arthritis. Vascul. Pharmacol. 2009, 51:1-7.
13. Szekanecz Z., Besenyei T., Szentpetery A., Koch A.E. Angiogenesis and vasculogenesis in rheumatoid arthritis. Curr. Opin. Rheumatol. 2010, 22:299-306.
14. Zhou H.F., Yan H., Senpan A., Wickline S.A., Pan D., Lanza G.M., et al. Suppression of inflammation in a mouse model of rheumatoid arthritis using targeted lipase-labile fumagillin prodrug nanoparticles. Biomaterials 2012, 33:8632-8640.
15. Gao W., Sweeney C., Walsh C., Rooney P., McCormick J., Veale D.J., et al. Notch signalling pathways mediate synovial angiogenesis in response to vascular endothelial growth factor and angiopoietin 2. Ann. Rheum. Dis. 2013, 72:1080-1088.
16. Jiao Z., Wang W., Ma J., Wang S., Su Z., Xu H. Notch signaling mediates TNF-α-induced IL-6 production in cultured fibroblast-like synoviocytes from rheumatoid arthritis. Clin. Dev. Immunol. 2011, 2012.
17. Gao W., Sweeney C., Connolly M., Kennedy A., Ng C.T., McCormick J., et al. Notch-1 mediates hypoxia-induced angiogenesis in rheumatoid arthritis. Arthritis Rheumatism 2012, 64:2104-2113.
18. Kochi Y., Suzuki A., Yamamoto K. Genetic basis of rheumatoid arthritis: a current review. Biochem. Biophys. Res. Commun. 2014, 452:254-262.
19. Lee Y.K., Mazmanian S.K. Has the microbiota played a critical role in the evolution of the adaptive immune system?. Science 2010, 330:1768-1773.
20. Liao K.P., Alfredsson L., Karlson E.W. Environmental influences on risk for rheumatoid arthritis. Curr. Opin. Rheumatol. 2009, 21:279.
21. Nishimura K., Sugiyama D., Kogata Y., Tsuji G., Nakazawa T., Kawano S., et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann. Intern. Med. 2007, 146:797-808.
22. Yukawa N., Fujii T., Kondo-Ishikawa S., Yoshifuji H., Kawabata D., Nojima T., et al. Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study. Arthritis Res. Ther. 2011, 13:R213.
23. Emery P., McInnes I., van Vollenhoven R., Kraan M. Clinical identification and treatment of a rapidly progressing disease state in patients with rheumatoid arthritis. Rheumatology 2008, 47:392-398.
24. St clair E.W., van der Heijde D.M., Smolen J.S., Maini R.N., Bathon J.M., Emery P., et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheumatism 2004, 50:3432-3443.
25. Trentham D.E., Townes A.S., Kang A.H. Autoimmunity to type II collagen an experimental model of arthritis. J. Exp. Med. 1977, 146:857-868.
26. Bader R.A. The Development of Targeted Drug Delivery Systems for Rheumatoid Arthritis Treatment 2012, INTECH Open Access Publisher.
27. Rao P., Knaus E.E. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J. Pharm. Pharm. Sci. 2008, 11:81-110.
28. Hoes J.N., Jacobs J.W., Buttgereit F., Bijlsma J.W. Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis. Nat. Rev. Rheumatol. 2010, 6:693-702.
29. von Vollenohower R. Treatment of rheumatoid arthritis: state of the art. Nat. Rev. Rheumatol. 2009, 5:531-541.
30. McInnes I.B., O'Dell J.R. State-of-the-art rheumatoid arthritis. Ann. Rheum. Dis. 2010, 69:1898-1906.
31. Šenolt L., Vencovský J., Pavelka K., Ospelt C., Gay S. Prospective new biological therapies for rheumatoid arthritis. Autoimmun. Rev. 2009, 9:102-107.
32. Meier F.M., Frerix M., Hermann W., Müller-Ladner U. Current immunotherapy in rheumatoid arthritis. Immunotherapy 2013, 5:955-974.
33. Salliot C., Finckh A., Katchamart W., Lu Y., Sun Y., Bombardier C., et al. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Ann. Rheum. Dis. 2011, 70:266-271.
34. Jorgensen C., Apparailly F. Prospects for gene therapy in inflammatory arthritis. Best Practice Res. Clin. Rheumatol. 2010, 24:541-552.
35. Lundin K.E., Simonson O.E., Moreno P.M., Zaghloul E.M., Oprea I.I., Svahn M.G., et al. Nanotechnology approaches for gene transfer. Genetica 2009, 137:47-56.
36. Parveen S., Misra R., Sahoo S.K. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomed. Nanotechnol. Biol. Med. 2012, 8:147-166.
37. Stevenson R., Hueber A.J., Hutton A., McInnes I.B., Graham D. Nanoparticles and inflammation. Sci. World J. 2011, 11:1300-1312.
38. Anselmo A.C., Mitragotri S. Cell-mediated delivery of nanoparticles: taking advantage of circulatory cells to target nanoparticles. J. Control. Release 2014, 190:531-541.
39. Wang E.C., Wang A.Z. Nanoparticles and their applications in cell and molecular biology. Integr. Biol. 2014, 6:9-26.
40. Brynskikh A.M., Zhao Y., Mosley R.L., Li S., Boska M.D., Klyachko N.L., et al. Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson's disease. Nanomedicine 2010, 5:379-396.
41. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 2005, 4:145-160.
42. Srinath P., Chary M., Vyas S., Diwan P. Long-circulating liposomes of indomethacin in arthritic rats-a biodisposition study. Pharm. Acta Helv. 2000, 74:399-404.
43. Palakurthi S., Vyas S., Diwan P. Biodisposition of PEG-coated lipid microspheres of indomethacin in arthritic rats. Int. J. Pharm. 2005, 290:55-62.
44. Bernardi A., Zilberstein A., Jäger E., Campos M., Morrone F., Calixto J., et al. Effects of indomethacin-loaded nanocapsules in experimental models of inflammation in rats. Br. J. Pharmacol. 2009, 158:1104-1111.
45. Metselaar J.M., Wauben M.H., Wagenaar-Hilbers J., Boerman O.C., Storm G. Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. Arthritis Rheumatism 2003, 48:2059-2066.
46. Koo O.M.Y., Rubinstein I., Önyüksel H. Actively targeted low-dose camptothecin as a safe, long-acting, disease-modifying nanomedicine for rheumatoid arthritis. Pharm. Res. 2011, 28:776-787.
47. Khoury M., Louis-Plence P., Escriou V., Noel D., Largeau C., Cantos C., et al. Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor α in experimental arthritis. Arthritis Rheumatism 2006, 54:1867-1877.
48. Torchilin V.P. Micellar nanocarriers: pharmaceutical perspectives. Pharm. Res. 2007, 24:1-16.
49. Grobmyer S.R., Iwakuma N., Sharma P., Moudgil B.M. What is Cancer Nanotechnology? 2010, Springer.
50. Medina S.H., El-Sayed M.E. Dendrimers as carriers for delivery of chemotherapeutic agents. Chem. Rev. 2009, 109:3141-3157.
51. Ishihara T., Kubota T., Choi T., Higaki M. Treatment of experimental arthritis with stealth-type polymeric nanoparticles encapsulating betamethasone phosphate. J. Pharmacol. Exp. Ther. 2009, 329:412-417.
52. Ishihara T., Takahashi M., Higaki M., Mizushima Y., Mizushima T. Preparation and characterization of a nanoparticulate formulation composed of PEG-PLA and PLA as anti-inflammatory agents. Int. J. Pharm. 2010, 385:170-175.
53. Hwang J., Rodgers K., Oliver J.C., Schluep T. α-Methylprednisolone conjugated cyclodextrin polymer-based nanoparticles for rheumatoid arthritis therapy. Int. J. Nanomed. 2008, 3:359.
54. Nagai N., Ito Y. Effect of solid nanoparticle of indomethacin on therapy for rheumatoid arthritis in adjuvant-Induced arthritis rat. Biol. Pharm. Bull. 2014, 37:1109-1118.
55. Nagai N., Yoshioka C., Ito Y. Topical therapies for rheumatoid arthritis by gel ointments containing indomethacin nanoparticles in adjuvant-Induced arthritis rat. J. Oleo. Sci. 2015, 64:337-346.
56. Nogueira E., Gomes A.C., Preto A., Cavaco-Paulo A. Folate-targeted nanoparticles for rheumatoid arthritis therapy. Nanomed. Nanotechnol. Biol. Med. 2015.
57. Thomas T.P., Goonewardena S.N., Majoros I.J., Kotlyar A., Cao Z., Leroueil P.R., et al. Folate-targeted nanoparticles show efficacy in the treatment of inflammatory arthritis. Arthritis Rheumatism 2011, 63:2671-2680.
58. Aggarwal B.B., Harikumar K.B. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int. J. Biochem. Cell Biol. 2009, 41:40-59.
59. A.K. Dewangan, S. Varkey, S., Mazumder Synthesis of Curcumin Loaded CMCAB Nanoparticles for Treatment of Rheumatoid Arthritis.
60. Arora R., Kuhad A., Kaur I., Chopra K. Curcumin loaded solid lipid nanoparticles ameliorate adjuvant-induced arthritis in rats. Eur. J. Pain 2015, 19:940-952.
61. Ye J., Wang Q., Zhou X., Zhang N. Injectable actarit-loaded solid lipid nanoparticles as passive targeting therapeutic agents for rheumatoid arthritis. Int. J. Pharm. 2008, 352:273-279.
62. Lee S.-M., Kim H.J., Ha Y.-J., Park Y.N., Lee S.-K., Park Y.-B., et al. Targeted chemo-photothermal treatments of rheumatoid arthritis using gold half-shell multifunctional nanoparticles. ACS Nano 2012, 7:50-57.
63. Scheinman R.I., Trivedi R., Vermillion S., Kompella U.B. Functionalized STAT1 siRNA nanoparticles regress rheumatoid arthritis in a mouse model. Nanomedicine 2011, 6:1669-1682.
64. Kim W.U., Lee W.K., Ryoo J.W., Kim S.H., Kim J., Youn J., et al. Suppression of collagen-induced arthritis by single administration of poly (lactic-co-glycolic acid) nanoparticles entrapping type II collagen: a novel treatment strategy for induction of oral tolerance. Arthritis Rheumatism 2002, 46:1109-1120.
65. Lee W.K., Park J.Y., Jung S., Yang C.W., Kim W.U., Kim H.Y., et al. Preparation and characterization of biodegradable nanoparticles entrapping immunodominant peptide conjugated with PEG for oral tolerance induction. J. Control. Release 2005, 105:77-88.
66. Runnels H.A., Weber G.L., Min J., Kudlacz E.M., Zobel J.F., Donovan C.B., et al. PF-03475952: a potent and neutralizing fully human anti-CD44 antibody for therapeutic applications in inflammatory diseases. Adv. Ther. 2010, 27:168-180.
67. Park J.-S., Kim S.-H., Kim K., Jin C.-H., Choi K.Y., Jang J., et al. Inhibition of Notch signalling ameliorates experimental inflammatory arthritis. Ann. Rheum. Dis. 2013, 10.1136/annrheumdis-2013-203467.
68. Heo R., Park J.S., Jang H.J., Kim S.-H., Shin J.M., Suh Y.D., et al. Hyaluronan nanoparticles bearing γ-secretase inhibitor: in vivo therapeutic effects on rheumatoid arthritis. J. Control. Release 2014, 192:295-300.
69. Zhou H.F., Chan H.W., Wickline S.A., Lanza G.M. Pham CT. αvβ3-Targeted nanotherapy suppresses inflammatory arthritis in mice. FASEB J. 2009, 23:2978-2985.
70. Ma A.C., Fung T.K., Lin R.H., Chung M.I., Yang D., Ekker S.C., et al. Methionine aminopeptidase 2 is required for HSC initiation and proliferation. Blood 2011, 118:5448-5457.
71. Zhou H.F., Hu G., Wickline S.A., Lanza G.M., Pham C.T. Synergistic effect of antiangiogenic nanotherapy combined with methotrexate in the treatment of experimental inflammatory arthritis. Nanomedicine 2010, 5:1065-1074.
72. Ahmed T.A., Aljaeid B.M. Preparation, characterization, and potential application of chitosan, chitosan derivatives, and chitosan metal nanoparticles in pharmaceutical drug delivery. Drug Design, Dev. Ther. 2016, 10:483.
73. Yuan Q., Hein S., Misra R. New generation of chitosan-encapsulated ZnO quantum dots loaded with drug: synthesis: characterization and in vitro drug delivery response. Acta Biomater. 2010, 6:2732-2739.
74. Mansouri S., Cuie Y., Winnik F., Shi Q., Lavigne P., Benderdour M., et al. Characterization of folate-chitosan-DNA nanoparticles for gene therapy. Biomaterials 2006, 27:2060-2065.
75. Prabaharan M. Chitosan-based nanoparticles for tumor-targeted drug delivery. Int. J. Biol. Macromol. 2015, 72:1313-1322.
76. Kim M.J., Park J.-S., Lee S.J., Jang J., Park J.S., Back S.H., et al. Notch1 targeting siRNA delivery nanoparticles for rheumatoid arthritis therapy. J. Control. Release 2015, 216:140-148.
77. Lee S.J., Lee A., Hwang S.R., Park J.-S., Jang J., Huh M.S., et al. TNF-α gene silencing using polymerized siRNA/thiolated glycol chitosan nanoparticles for rheumatoid arthritis. Mol. Ther. 2014, 22:397-408.
78. Fernandes J.C., Wang H., Jreyssaty C., Benderdour M., Lavigne P., Qiu X., et al. Bone-protective effects of nonviral gene therapy with Folate-Chitosan DNA nanoparticle containing Interleukin-1 receptor antagonist gene in rats with adjuvant-induced arthritis. Mol. Ther. 2008, 16:1243-1251.
79. Courties G., Baron M., Presumey J., Escriou V., van Lent P., Scherman D., et al. Cytosolic phospholipase A2α gene silencing in the myeloid lineage alters development of Th1 responses and reduces disease severity in collagen-induced arthritis. Arthritis Rheumatism 2011, 63:681-690.
80. Samarasinghe R.M., Kanwar R.K., Kanwar J.R. The effect of oral administration of iron saturated-bovine lactoferrin encapsulated chitosan-nanocarriers on osteoarthritis. Biomaterials 2014, 35:7522-7534.
81. Danhier F., Ansorena E., Silva J.M., Coco R., Le Breton A. Préat V.PLGA-based nanoparticles: an overview of biomedical applications. J. Control. Release 2012, 161:505-522.
82. Weissleder R. Molecular imaging in cancer. Science 2006, 312:1168-1171.
83. Wang Y.-X.J., Hussain S.M., Krestin G.P. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur. Radiol. 2001, 11:2319-2331.
84. Zhao M., Beauregard D.A., Loizou L., Davletov B., Brindle K.M. Non-invasive detection of apoptosis using magnetic resonance imaging and a targeted contrast agent. Nat. Med. 2001, 7:1241-1244.
85. Ringe J., Sittinger M. Tissue engineering in the rheumatic diseases. Arthritis Res. Ther. 2009, 11:211.
86. Bouffi C., Djouad F., Mathieu M., Noël D., Jorgensen C. Multipotent mesenchymal stromal cells and rheumatoid arthritis: risk or benefit. Rheumatology 2009, 48:1185-1189.
87. Chen Y., Shao J.-Z., Xiang L.-X., Dong X.-J., Zhang G.-R. Mesenchymal stem cells: a promising candidate in regenerative medicine. Int. J. Biochem. Cell Biol. 2008, 40:815-820.
88. Jones B.J., McTaggart S.J. Immunosuppression by mesenchymal stromal cells: from culture to clinic. Exp. Hematol. 2008, 36:733-741.
89. Markides H., Kehoe O., Morris R.H., El Haj A.J. Whole body tracking of superparamagnetic iron oxide nanoparticle-labelled cells-a rheumatoid arthritis mouse model. Stem Cell Res. Ther. 2013, 4:126.
90. Saldanha K.J., Doan R.P., Ainslie K.M., Desai T.A., Majumdar S. Micrometer-sized iron oxide particle labeling of mesenchymal stem cells for magnetic resonance imaging-based monitoring of cartilage tissue engineering. Magn. Reson. Imaging 2011, 29:40-49.
91. He G., Zhang H., Wei H., Wang Y., Zhang X., Tang Y., et al. In vivo imaging of bone marrow mesenchymal stem cells transplanted into myocardium using magnetic resonance imaging: a novel method to trace the transplanted cells. Int. J. Cardiol. 2007, 114:4-10.
92. Kim T.H., Kim J.K., Shim W., Kim S.Y., Park T.J., Jung J.Y. Tracking of transplanted mesenchymal stem cells labeled with fluorescent magnetic nanoparticle in liver cirrhosis rat model with 3-T MRI. Magn. Reson. Imaging 2010, 28:1004-1013.
93. Kim H.S., Oh S.Y., Joo H.J., Son K.R., Song I.C., Moon W.K. The effects of clinically used MRI contrast agents on the biological properties of human mesenchymal stem cells. NMR Biomed. 2010, 23:514-522.
94. Duan J., Dong J., Zhang T., Su Z., Ding J., Zhang Y., et al. Polyethyleneimine-functionalized iron oxide nanoparticles for systemic siRNA delivery in experimental arthritis. Nanomedicine 2014, 9:789-801.
95. X. Huang, Jain PK, El-Sayed IH, El-Sayed MA. Gold nanoparticles: interesting optical properties and recent applications in cancer diagnostics and therapy. (2007).
96. Peng G., Tisch U., Adams O., Hakim M., Shehada N., Broza Y.Y., et al. Diagnosing lung cancer in exhaled breath using gold nanoparticles. Nat. Nanotechnol. 2009, 4:669-673.
97. Liu X., Dai Q., Austin L., Coutts J., Knowles G., Zou J., et al. A one-step homogeneous immunoassay for cancer biomarker detection using gold nanoparticle probes coupled with dynamic light scattering. J. Amer. Chem. Soc. 2008, 130:2780-2782.
98. Huang X., El-Sayed I.H., Qian W., El-Sayed M.A. Cancer cell imaging and photothermal therapy in the near-infrared region by using gold nanorods. J. Amer. Chem. Soc. 2006, 128:2115-2120.
99. Mukherjee P., Bhattacharya R., Wang P., Wang L., Basu S., Nagy J.A., et al. Antiangiogenic properties of gold nanoparticles. Clin. Cancer Res. 2005, 11:3530-3534.
100. Brown C., Whitehouse M., Tiekink E.R.T., Bushell G.R. Colloidal metallic gold is not bio-inert. Inflammopharmacology 2008, 16:133-137.
101. Ma J.S., Kim W.J., Kim J.J., Kim T.J., Ye S.K., Song M.D., et al. Gold nanoparticles attenuate LPS-induced NO. production through the inhibition of NF-κB and IFN-β/STAT1 pathways in RAW264. 7 cells. Nitric Oxide 2010, 23:214-219.
102. James L.R., Xu Z.-Q., Sluyter R., Hawksworth E.L., Kelso C., Lai B., et al. An investigation into the interactions of gold nanoparticles and anti-arthritic drugs with macrophages, and their reactivity towards thioredoxin reductase. J. Inorg. Biochem. 2015, 142:28-38.
103. Lee H., Lee M.-Y., Bhang S.H., Kim B.-S., Kim Y.S., Ju J.H., et al. Hyaluronate-Gold Nanoparticle/Tocilizumab complex for the treatment of rheumatoid arthritis. ACS Nano 2014, 8:4790-4798.
104. Elsadek B., Kratz F. Impact of albumin on drug delivery-New applications on the horizon. J. Control. Release 2012, 157:4-28.
105. Gradishar W.J., Tjulandin S., Davidson N., Shaw H., Desai N., Bhar P., et al. Phase III. trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 2005, 23:7794-7803.
106. Hawkins M.J., Soon-Shiong P., Desai N. Protein nanoparticles as drug carriers in clinical medicine. Adv. Drug Deliv. Rev. 2008, 60:876-885.
107. Neumann E., Frei E., Funk D., Becker M.D., Schrenk H.-H., Müller-Ladner U., et al. Native albumin for targeted drug delivery. Expert Opin. Drug Deliv. 2010, 7:915-925.
108. Fiehn C., Neumann E., Wunder A., Krienke S., Gay S., Müller-Ladner U. Methotrexate (MTX) and albumin coupled with MTX (MTX-HSA) suppress synovial fibroblast invasion and cartilage degradation in vivo. Ann. Rheum. Dis. 2004, 63:884-886.
109. Patel P., Patel H., Panchal S., Mehta T. Formulation strategies for drug delivery of tacrolimus: an overview. Int. J. Pharm. Invest. 2012, 2:169.
110. Byeon H.J., Lee C., Lee S., Lee E.S., Choi H.-G., Park E.-S., et al. Pharmaceutical potential of tacrolimus-loaded albumin nanoparticles having targetability to rheumatoid arthritis tissues. Int. J. Pharm. 2016, 497:268-276.
111. Blanco E., Hsiao A., Mann A.P., Landry M.G., Meric-Bernstam F., Ferrari M. Nanomedicine in cancer therapy: innovative trends and prospects. Cancer Sci. 2011, 102:1247-1252.
112. Coppieters K., Dreier T., Silence K., Haard H.D., Lauwereys M., Casteels P., et al. Formatted anti?tumor necrosis factor α VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. Arthritis Rheumatism 2006, 54:1856-1866.
113. Ren K., Dusad A., Dong R., Quan L. Albumin as a delivery carrier for rheumatoid arthritis. J. Nanomed. Nanotechol. 2013, 4:2.
114. Liu M., Huang Y., Hu L., Liu G., Hu X., Liu D., et al. Selective delivery of interleukine-1 receptor antagonist to inflamed joint by albumin fusion. BMC Biotechnol. 2012, 12:68.